1-18 of 18
Lysiane Molina
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Anne Sophie Michallet, Remi Letestu, Magali Legarff, Stéphane Morisset, Therese Aurran-Schleinitz, Kamel Laribi, Vincent Levy, Laurence Simon, Damien Roos Weil, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc-Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Omar Benbrahim, Xavier Cahu, Florence Nguyen Khac, Valerie Rouillé, Loic Ysebaert, Anne Quinquenel
Journal: Blood
Blood (2024) 144 (Supplement 1): 584.
https://doi.org/10.1182/blood-2024-194593
Published: 2024
Journal Articles

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Luc-Matthieu Fornecker, Rémi Letestu, Nanthara Shritaran, Emmanuelle Ferrant, Fressia Honeyman, Therese Aurran-Schleinitz, Fatiha Merabet, Pierre Morel, Abderrazak El Yamani, Jehan Dupuis, Kamel Laribi, Stephane Lepretre, Lysiane Molina, Hugo Legendre, Chadi Al Nawakil, Bruno Villemagne, Anne-Sophie Michallet, Béatrice Mahé, Omar Benbrahim, Laurence Sanhes, Caroline Dartigeas, Aline Clavert, Vincent Levy
Journal: Blood
Blood (2024) 144 (Supplement 1): 3256.
https://doi.org/10.1182/blood-2024-203081
Published: 2024
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Tavernier Magali, Stéphane Morisset, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos Weil, Veronique Leblond, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valerie Rouillé, Alain Jacques Delmer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3268.
https://doi.org/10.1182/blood-2023-173341
Published: 2023
Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer
Journal: Blood
Blood (2022) 140 (Supplement 1): 7030–7031.
https://doi.org/10.1182/blood-2022-163096
Published: 2022
Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Christelle Portois, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan, Jean-Pierre Vilque, Therese Aurran Schleinitz, Cymbalista Florence, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen Khac, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 7013–7015.
https://doi.org/10.1182/blood-2022-157963
Published: 2022
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, Anne-Sophie Michallet
Journal: Blood
Blood (2022) 140 (Supplement 1): 7007–7009.
https://doi.org/10.1182/blood-2022-159678
Published: 2022
Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Luc-Matthieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran-Schleinitz, Aline Clavert, Sophie de Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drenou, Philippe Quittet, Benedicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 6631–6632.
https://doi.org/10.1182/blood-2022-159695
Published: 2022
Journal Articles

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Clinical Trials & Observations
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Emmanuelle Nicolas Virelizier, Marie Maerevoet, Christophe Fruchart, Sylvia Snauwaert, Steven Le Gouill, Jean-Pierre Marolleau, Lysiane Molina, Cécile Moluçon-Chabrot, Catherine Thieblemont, Hervé Tilly, Fontanet Bijou, Corinne Haioun, Eric Van den Neste, Bettina Fabiani, Michel Meignan, Guillaume Cartron, Gilles Salles, Olivier Casasnovas, Franck Morschhauser
Journal: Blood
Blood (2022) 139 (15): 2338–2346.
https://doi.org/10.1182/blood.2021013526
Published: 2022
Includes: Supplemental data
Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Lysiane Molina, Luc Mathieu Fornecker, Thérèse Aurran, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Alain Saad, Sophie de Guibert, Bernard Drenou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood
Blood (2021) 138 (Supplement 1): 3570.
https://doi.org/10.1182/blood-2021-147467
Published: 2021
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Mad-Helenie Elsensohn, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Veronique Leblond, Marie-Sarah Dilhuydy, Cécile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Leprêtre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen-Khac, Valérie Rouille, Alain Delmer
Journal: Blood
Blood (2021) 138 (Supplement 1): 641.
https://doi.org/10.1182/blood-2021-145624
Published: 2021
Journal Articles

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Julien Lazarovici, Sandy Amorim, Krimo Bouabdallah, Stéphanie Guidez, Lysiane Molina, Franck Morschhauser, Anne-Claire Gac, Thomas Gastinne, Kamel Laribi, Vincent Launay, Bohrane Slama, Nawel Belmecheri, René-Olivier Casasnovas, Anne Corby, Eric Durot, Pierre Feugier, Emmanuelle Nicolas-Virelizier, David Sibon, Alina Berriolo-Riedinger, Veronique Edeline, Thierry Vander Borght, Diane Damotte, Alexandra Traverse-Glehen, Marc Andre, Vincent Ribrag
Journal: Blood
Blood (2021) 138 (Supplement 1): 232.
https://doi.org/10.1182/blood-2021-147863
Published: 2021
Journal Articles

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Romain Guieze, MD, Loic Ysebaert, MD PhD, Lysiane Molina, MD, Damien Roos-Weil, MDPhD, Anne-Sophie Michallet, MD PhD, Benedicte Hivert, MD, Julie Gay, MD, Alain Saad, MD, Luc Mathieu Fornecker, MD PhD, Julien Broséus, Valérie Rouille, Laëtitia Auvray, Alain Jacques Delmer, MD PhD, Pierre Feugier, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-136667
Published: 2020
Journal Articles

A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy

Franck Morschhauser, MD, Gilles Andre Salles, Rene-Olivier Casasnovas, MD, Pierre Feugier, Krimo Bouabdallah, MD, Guillaume Cartron, Reda Bouabdallah, MD, Emmanuelle Nicolas-Virelizier, MD, Marie Maerevoet, MD, Sylvia Snauwaert, Christophe Fruchart, Steven LE Gouill, MD PhD, Cécile Moluçon-Chabrot, MD PhD, Caroline Delette, Lysiane Molina, MD, Herve Tilly, MD, Catherine Thieblemont, MD, Eric Van Den Neste, Fontanet Bijou, MD, Bettina Fabiani, MD, Corinne Haioun, MD, Roch Houot, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 446.
https://doi.org/10.1182/blood-2018-99-112805
Published: 2018
Journal Articles

Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program

Guillaume Manson, MD, Jean-Baptiste Mear, MD, Charles Herbaux, MD, Jean Marc Schiano de Collela, MD, Rene-Olivier Casasnovas, MD, Aspasia Stamatoullas, MD, Bénédicte Deau-Fisher, MD, Anna Schmitt, Georges Garnier, MD, Lysiane Molina, MD, Krimo Bouabdallah, MD, Marie-Pierre Moles, Herv Ghesquieres, Adrian Tempescul, MD, Remy Dulery, MD, Emmanuelle Nicolas-Virelizier, MD, Alain Jacques Delmer, MD, Cecile Borel, MD, Adrien Chauchet, MD, Laurent Dercle, MD, Pauline Brice, MD, Roch Houot, Pr, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1638.
https://doi.org/10.1182/blood-2018-99-110960
Published: 2018
Journal Articles

PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007

Sylvain Carras, MD, Benjamin Dubois, Delphine Senecal, MD, Philippe Quittet, MD, jean-Philippe Vuillez, MD PhD, Michel peoc'H, MD PhD, jean-Philippe Jais, Thierry Lamy, MDPhD, Lysiane Molina, MD
Journal: Blood
Blood (2015) 126 (23): 3932.
https://doi.org/10.1182/blood.V126.23.3932.3932
Published: 2015
Journal Articles

High Intermittent Dose of Chlorambucil Associated with Rituximab Is a Promising Treatment of Elderly Patients with Indolent Lymphoma.

Laingo Andrianarison, Stephane Courby, Blandine Fabre, Lysiane Molina, Valerie Legrand, Brigitte Pegourie Bandelier, Audrey Simon, Clara Mariette, Claire Vettier, Christine Lefebvre, Frederic Garban, Claude Eric Bulabois, Anne Thiebaut, Jean Yves Cahn, Remy Gressin
Journal: Blood
Blood (2009) 114 (22): 4761.
https://doi.org/10.1182/blood.V114.22.4761.4761
Published: 2009
Journal Articles

A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.

Eric Jourdan, Françoise Rigal-Huguet, Gérald Marit, Norbert Vey, Nicole Dastugue, Nathalie Fegueux, Lysiane Molina, Jean-Albert Gastaut, Laurence Legros, Hacene Zerazhi, Sylvie Cailleres, Frédéric Bauduer, Dominique Bordessoule, Michel Attal, Didier Blaise, Arnaud Pigneux
Journal: Blood
Blood (2004) 104 (11): 5194.
https://doi.org/10.1182/blood.V104.11.5194.5194
Published: 2004
Journal Articles

Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.

Eric Jourdan, Jean-Michel Boiron, Nicole Dastugue, Norbert Vey, Gérald Marit, Françoise Rigal-Huguet, Lysiane Molina, Nathalie Fegueux, Arnaud Pigneux, Christian Recher, Jean-François Rossi, Michel Attal, Jean-Jacques Sotto, Dominique Maraninchi, Josy Reiffers, Valérie-Jeanne Bardou, Didier Blaise
Journal: Blood
Blood (2004) 104 (11): 619.
https://doi.org/10.1182/blood.V104.11.619.619
Published: 2004